Seelos therapeutics receives a notice of allowance in the u.s. for an additional patent for sls-007

New york , may 18, 2022 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a notice of allowance for u.s. patent application number 16/833,515 from the united states patent and trademark office (uspto) covering sls-007 titled: "structure-based peptide inhibitors of alpha-synuclein aggregation". this notice of allowance covers the method of treating several neurodegenerative diseases such as alzheimer's disease, parkinson's disease (pd), lewy body dementia and multiple system atrophy, through contacting alpha-synuclein (Α-synuclein) protofilaments with an effective amount of sls-007.
SEEL Ratings Summary
SEEL Quant Ranking